These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 24803876)

  • 41. Epidemiology and surveillance of hepatocellular carcinoma.
    Kim DY; Han KH
    Liver Cancer; 2012 Jun; 1(1):2-14. PubMed ID: 24159567
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Surveillance for hepatocellular carcinoma.
    Díaz-González Á; Forner A
    Best Pract Res Clin Gastroenterol; 2016 Dec; 30(6):1001-1010. PubMed ID: 27938779
    [TBL] [Abstract][Full Text] [Related]  

  • 43. DNA markers in molecular diagnostics for hepatocellular carcinoma.
    Su YH; Lin SY; Song W; Jain S
    Expert Rev Mol Diagn; 2014 Sep; 14(7):803-17. PubMed ID: 25098554
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Biomarkers for Hepatocellular Carcinoma (HCC): An Update.
    Li D; Satomura S
    Adv Exp Med Biol; 2015; 867():179-93. PubMed ID: 26530367
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Surveillance for hepatocellular carcinoma.
    Sherman M
    Best Pract Res Clin Gastroenterol; 2014 Oct; 28(5):783-93. PubMed ID: 25260308
    [TBL] [Abstract][Full Text] [Related]  

  • 46. α-Fetoprotein in hepatocellular carcinoma surveillance: mend it but do not end it.
    El-Serag HB; Kanwal F
    Clin Gastroenterol Hepatol; 2013 Apr; 11(4):441-3. PubMed ID: 23376321
    [No Abstract]   [Full Text] [Related]  

  • 47. Hepatocellular carcinoma detected by regular surveillance: Does timely confirmation of diagnosis matter?
    Yeh JH; Hung CH; Wang JH; Kuo YH; Tai WC; Lu SN
    Dig Liver Dis; 2016 Jun; 48(6):661-6. PubMed ID: 26992848
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The search for biomarkers of hepatocellular carcinoma and the impact on patient outcome.
    Black AP; Mehta AS
    Curr Opin Pharmacol; 2018 Aug; 41():74-78. PubMed ID: 29772420
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of biannual ultrasonography and annual non-contrast liver magnetic resonance imaging as surveillance tools for hepatocellular carcinoma in patients with liver cirrhosis (MAGNUS-HCC): a study protocol.
    Kim HA; Kim KA; Choi JI; Lee JM; Lee CH; Kang TW; Ku YM; Lee SL; Park YS; Yoon JH; Kim SH; Choi MH
    BMC Cancer; 2017 Dec; 17(1):877. PubMed ID: 29268722
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma.
    Lok AS; Sterling RK; Everhart JE; Wright EC; Hoefs JC; Di Bisceglie AM; Morgan TR; Kim HY; Lee WM; Bonkovsky HL; Dienstag JL;
    Gastroenterology; 2010 Feb; 138(2):493-502. PubMed ID: 19852963
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Circulating predictive and diagnostic biomarkers for hepatitis B virus-associated hepatocellular carcinoma.
    Van Hees S; Michielsen P; Vanwolleghem T
    World J Gastroenterol; 2016 Oct; 22(37):8271-8282. PubMed ID: 27729734
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Serum miR-483-5p and miR-133a as Biomarkers for Diagnosis of Hepatocellular Carcinoma Post-Hepatitis C Infection in Egyptian Patients.
    Hassan AS; Elgendy NA; Tawfik NA; Elnasser AM
    Egypt J Immunol; 2019 Jul; 26(2):31-40. PubMed ID: 31926493
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Promising Urinary Protein Biomarkers for the Early Detection of Hepatocellular Carcinoma among High-Risk Hepatitis C Virus Egyptian Patients.
    Abdalla MA; Haj-Ahmad Y
    J Cancer; 2012; 3():390-403. PubMed ID: 23074380
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Biomarkers for the early diagnosis of hepatocellular carcinoma.
    Tsuchiya N; Sawada Y; Endo I; Saito K; Uemura Y; Nakatsura T
    World J Gastroenterol; 2015 Oct; 21(37):10573-83. PubMed ID: 26457017
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Surveillance for hepatocellular carcinoma.
    Frenette C
    Clin Adv Hematol Oncol; 2016 Jun; 14(6):407-9. PubMed ID: 27379808
    [No Abstract]   [Full Text] [Related]  

  • 56. Hepatocellular carcinoma surveillance with miRNAs.
    Forner A
    Lancet Oncol; 2015 Jul; 16(7):743-5. PubMed ID: 26088271
    [No Abstract]   [Full Text] [Related]  

  • 57. Liquid biopsy in the clinical management of hepatocellular carcinoma.
    von Felden J; Garcia-Lezana T; Schulze K; Losic B; Villanueva A
    Gut; 2020 Nov; 69(11):2025-2034. PubMed ID: 32883873
    [TBL] [Abstract][Full Text] [Related]  

  • 58. AFP, PIVKAII, GP3, SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver disease.
    Beale G; Chattopadhyay D; Gray J; Stewart S; Hudson M; Day C; Trerotoli P; Giannelli G; Manas D; Reeves H
    BMC Cancer; 2008 Jul; 8():200. PubMed ID: 18638391
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Early detection of hepatocellular carcinoma using autoantibody profiles from a panel of tumor-associated antigens.
    Koziol JA; Imai H; Dai L; Zhang JY; Tan EM
    Cancer Immunol Immunother; 2018 May; 67(5):835-841. PubMed ID: 29497780
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Hepatocellular carcinoma surveillance with ultrasound-cost-effectiveness, high-risk populations, uptake.
    Ronot M; Pommier R; Dioguardi Burgio M; Purcell Y; Nahon P; Vilgrain V
    Br J Radiol; 2018 Oct; 91(1090):20170436. PubMed ID: 29446324
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.